Mumbai based Aanjaneya Lifecare has received the certificate of suitability (CEP) from EDQM for two of its bulk drugs Quinine Sulphate & Quinine Hydrochloride. As one of world’s largest producers of Quinine Salts, this certification opens the gates for a huge market in Europe for Aanjaneya Lifecare.
The anti-Malarial segment is fast growing segment with large generic players from Europe including Teva, Actavis, Sanofi Aventis, Mylan etc being the dominant players. Aanjaneya has commenced supply of product Quinine Sulphate to pharmaceutical major Teva earlier this year.
The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (API). APIs, also known as bulk drugs‘ or bulk actives‘ are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients. The company specializes in anti-malaria drugs and Finished Dosage Forms (FDFs) for various therapeutic segments.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1872.75 |
| Dr. Reddys Lab | 1289.80 |
| Cipla | 1308.60 |
| Zydus Lifesciences | 954.90 |
| Lupin | 2280.95 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: